1
|
Polykretis P, D’Andrea C, Banchelli M, Napolitano L, Cascella R, de Angelis M, Matteini P. Exploring the Aβ 1-42 fibrillogenesis timeline by atomic force microscopy and surface enhanced Raman spectroscopy. Front Mol Biosci 2024; 11:1376411. [PMID: 38948077 PMCID: PMC11211275 DOI: 10.3389/fmolb.2024.1376411] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2024] [Accepted: 05/22/2024] [Indexed: 07/02/2024] Open
Abstract
Introduction: Alzheimer's disease (AD) is a progressive debilitating neurological disorder representing the most common neurodegenerative disease worldwide. Although the exact pathogenic mechanisms of AD remain unresolved, the presence of extracellular amyloid-β peptide 1-42 (Aβ1-42) plaques in the parenchymal and cortical brain is considered one of the hallmarks of the disease. Methods: In this work, we investigated the Aβ1-42 fibrillogenesis timeline up to 48 h of incubation, providing morphological and chemo-structural characterization of the main assemblies formed during the aggregation process of Aβ1-42, by atomic force microscopy (AFM) and surface enhanced Raman spectroscopy (SERS), respectively. Results: AFM topography evidenced the presence of characteristic protofibrils at early-stages of aggregation, which form peculiar macromolecular networks over time. SERS allowed to track the progressive variation in the secondary structure of the aggregation species involved in the fibrillogenesis and to determine when the β-sheet starts to prevail over the random coil conformation in the aggregation process. Discussion: Our research highlights the significance of investigating the early phases of fibrillogenesis to better understand the molecular pathophysiology of AD and identify potential therapeutic targets that may prevent or slow down the aggregation process.
Collapse
Affiliation(s)
- Panagis Polykretis
- Institute of Applied Physics “Nello Carrara”, National Research Council, Sesto Fiorentino, Italy
| | - Cristiano D’Andrea
- Institute of Applied Physics “Nello Carrara”, National Research Council, Sesto Fiorentino, Italy
| | - Martina Banchelli
- Institute of Applied Physics “Nello Carrara”, National Research Council, Sesto Fiorentino, Italy
| | - Liliana Napolitano
- Department of Experimental and Clinical Biomedical Sciences, Section of Biochemistry, University of Florence, Florence, Italy
| | - Roberta Cascella
- Department of Experimental and Clinical Biomedical Sciences, Section of Biochemistry, University of Florence, Florence, Italy
| | - Marella de Angelis
- Institute of Applied Physics “Nello Carrara”, National Research Council, Sesto Fiorentino, Italy
| | - Paolo Matteini
- Institute of Applied Physics “Nello Carrara”, National Research Council, Sesto Fiorentino, Italy
| |
Collapse
|
2
|
An electrochemiluminescence aptasensor for amyloid-β protein with signal enhancement from AuNPs/Fe-MOFs nanocomposite. J Electroanal Chem (Lausanne) 2023. [DOI: 10.1016/j.jelechem.2023.117293] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/04/2023]
|
3
|
Sun L, Lei Y, Wang Y, Liu D. Blood-based Alzheimer's disease diagnosis using fluorescent peptide nanoparticle arrays. CHINESE CHEM LETT 2022. [DOI: 10.1016/j.cclet.2021.10.071] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
4
|
Liu D, Fu D, Zhang L, Sun L. Detection of amyloid-beta by Fmoc-KLVFF self-assembled fluorescent nanoparticles for Alzheimer’s disease diagnosis. CHINESE CHEM LETT 2021. [DOI: 10.1016/j.cclet.2020.09.009] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
|
5
|
Yin L, Wang Y, Tan R, Li H, Tu Y. Determination of β-amyloid oligomer using electrochemiluminescent aptasensor with signal enhancement by AuNP/MOF nanocomposite. Mikrochim Acta 2021; 188:53. [PMID: 33496823 DOI: 10.1007/s00604-021-04710-7] [Citation(s) in RCA: 27] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2020] [Accepted: 01/10/2021] [Indexed: 01/17/2023]
Abstract
In order to effectively and conveniently detect the β-amyloid oligomer (AβO) for earlier diagnosis of Alzheimer's disease (AD), a disposable aptamer biosensor has been developed with high performance, facile operation, and low cost. Using a nanocomposite by in situ reduction of chloroauric acid to decorate Au nanoparticles (AuNPs) on Fe-MIL-88NH2 material via Au-N bond to effectively enhance the electrochemiluminescence (ECL) of luminol, the functioned basal electrode provides adequate background for sensing response. When the aptamer is linked via Au-S bond on the surface, the sensor gets the ability of specific recognition and coalescence toward the target (AβO). After incubating the sample on the aptasensor, its ECL signal is inhibited owing to the steric hindrance of the AβO macromolecules. The relative inhibition ratio linearly depends to the logarithm of AβO concentration in the range 0.1 pM to 10 pM, with an LOD of 71 fM. The aptasensor has high selectivity to AβO among its analogs. The recoveries in human serum were 98.9-105.4%. This research provides a new approach for sensitive detection of AβO in clinic laboratories for investigation and diagnosis of AD.
Collapse
Affiliation(s)
- Lixiu Yin
- College of Chemistry, Chemical Engineering and Material Science, Soochow University, Suzhou, 215123, People's Republic of China
| | - Yueju Wang
- First Affiliated Hospital of Soochow University, Suzhou, 215006, People's Republic of China
| | - Rong Tan
- College of Chemistry, Chemical Engineering and Material Science, Soochow University, Suzhou, 215123, People's Republic of China
| | - Huiling Li
- First Affiliated Hospital of Soochow University, Suzhou, 215006, People's Republic of China.
| | - Yifeng Tu
- College of Chemistry, Chemical Engineering and Material Science, Soochow University, Suzhou, 215123, People's Republic of China.
| |
Collapse
|
6
|
Meng X, Li T, Wang X, Lv X, Sun Z, Zhang J, Su F, Kang S, Kim S, An SSA, Yu X, Zhang C, Wang H. Association between increased levels of amyloid-β oligomers in plasma and episodic memory loss in Alzheimer's disease. ALZHEIMERS RESEARCH & THERAPY 2019; 11:89. [PMID: 31651358 PMCID: PMC6814096 DOI: 10.1186/s13195-019-0535-7] [Citation(s) in RCA: 32] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/01/2019] [Accepted: 08/26/2019] [Indexed: 01/10/2023]
Abstract
Objective The objectives of this study were to investigate whether the plasma levels of oligomeric amyloid-β (OAβ) were affected in Alzheimer’s disease (AD) and to examine the associations (or possible correlations) between plasma OAβ levels and memory performance. Method Thirty subjects with AD and 28 cognitively normal controls were recruited in the study. The multimer detection system (MDS) was used to measure the levels of OAβ in the plasma. In addition to assessing the general cognitive function with the Mini-Mental State Examination (MMSE), Cognitive Abilities Screening Instrument (CASI), and Alzheimer’s Disease Assessment Scale–cognitive portion (ADAS-Cog), the common objects memory test (COMT) was used to examine the episodic memory performance. Pearson’s and partial correlation analyses were conducted to explore the associations between cognitive performance and OAβ levels in the plasma. A receiving operating curve (ROC) analysis was used to discriminate between the AD and control groups. Results The plasma OAβ levels in the AD group were significantly higher than those in the control group [1.88 (0.38) ng/ml vs 1.20 (0.40) ng/ml, p < 0.001]. The elevated levels of plasma OAβ showed a strong correlation with cognitive performance in patients with AD, including an inverse correlation with scores on the MMSE (r = − 0.43, p = 0.02), CASI (r = − 0.56, p < 0.01), and the immediate recall (r = − 0.45, p = 0.01), 5-min delayed recall (r = − 0.56, p < 0.01), and 30-min delayed recall (r = − 0.71, p < 0.001) tests of the COMT, and a positive correlation with the ADAS-Cog scores (r = 0.59, p < 0.001). The EDTA plasma Aβ oligomer optical density (OD) value measured using the MDS could discriminate between the AD and control groups with an area under the curve (AUC) of 0.89. The optimal sensitivity and specificity were 82.1% and 90.0%, respectively. Conclusion The elevated levels of OAβ in the plasma distinguished the AD and control groups and were associated with the severity of symptoms, especially memory performance, in patients with AD. Our results suggested that plasma OAβ could potentially be a simple and non-invasive blood-based biomarker for AD diagnosis. Furthermore, longitudinal studies are warranted to explore the application of plasma OAβ levels as a valid diagnostic biomarker in patients with AD. Electronic supplementary material The online version of this article (10.1186/s13195-019-0535-7) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Xue Meng
- Dementia Care and Research Center, Beijing Key Laboratory for Translational Research on Diagnosis and Treatment of Dementia, Peking University Institute of Mental Health (Sixth Hospital), Beijing, 100191, China.,National Clinical Research Center for Mental Disorders, Key Laboratory for Mental Health, National Health Commission, Beijing, 100191, China.,State Key Laboratory of Membrane Biology, School of Life Sciences, PKU-IDG/McGovern Institute for Brain Research, Peking University, Beijing, 100871, China
| | - Tao Li
- Dementia Care and Research Center, Beijing Key Laboratory for Translational Research on Diagnosis and Treatment of Dementia, Peking University Institute of Mental Health (Sixth Hospital), Beijing, 100191, China.,National Clinical Research Center for Mental Disorders, Key Laboratory for Mental Health, National Health Commission, Beijing, 100191, China
| | - Xiao Wang
- Dementia Care and Research Center, Beijing Key Laboratory for Translational Research on Diagnosis and Treatment of Dementia, Peking University Institute of Mental Health (Sixth Hospital), Beijing, 100191, China.,National Clinical Research Center for Mental Disorders, Key Laboratory for Mental Health, National Health Commission, Beijing, 100191, China
| | - Xiaozhen Lv
- Dementia Care and Research Center, Beijing Key Laboratory for Translational Research on Diagnosis and Treatment of Dementia, Peking University Institute of Mental Health (Sixth Hospital), Beijing, 100191, China.,National Clinical Research Center for Mental Disorders, Key Laboratory for Mental Health, National Health Commission, Beijing, 100191, China
| | - Zhiyu Sun
- Dementia Care and Research Center, Beijing Key Laboratory for Translational Research on Diagnosis and Treatment of Dementia, Peking University Institute of Mental Health (Sixth Hospital), Beijing, 100191, China
| | - Jichun Zhang
- Dementia Care and Research Center, Beijing Key Laboratory for Translational Research on Diagnosis and Treatment of Dementia, Peking University Institute of Mental Health (Sixth Hospital), Beijing, 100191, China.,State Key Laboratory of Membrane Biology, School of Life Sciences, PKU-IDG/McGovern Institute for Brain Research, Peking University, Beijing, 100871, China
| | - Feng Su
- State Key Laboratory of Membrane Biology, School of Life Sciences, PKU-IDG/McGovern Institute for Brain Research, Peking University, Beijing, 100871, China
| | - Sungmin Kang
- Department of Research and Development, PeopleBio, Inc., Seongnam-si, Gyeonggi-do, Republic of Korea
| | - SangYun Kim
- Department of Neurology, Seoul National University Bundang Hospital and Seoul National University College of Medicine, 82, Gumi-ro 173, Bundang-gu, Seongnam-si, Gyeonggi-do, 463-707, Republic of Korea
| | - Seong Soo A An
- Department of Bionano Technology, Gachon University, Sujeong-gu, Seongnam-si, Gyeonggi-do, 461-701, Republic of Korea
| | - Xin Yu
- Dementia Care and Research Center, Beijing Key Laboratory for Translational Research on Diagnosis and Treatment of Dementia, Peking University Institute of Mental Health (Sixth Hospital), Beijing, 100191, China. .,National Clinical Research Center for Mental Disorders, Key Laboratory for Mental Health, National Health Commission, Beijing, 100191, China.
| | - Chen Zhang
- State Key Laboratory of Membrane Biology, School of Life Sciences, PKU-IDG/McGovern Institute for Brain Research, Peking University, Beijing, 100871, China.
| | - Huali Wang
- Dementia Care and Research Center, Beijing Key Laboratory for Translational Research on Diagnosis and Treatment of Dementia, Peking University Institute of Mental Health (Sixth Hospital), Beijing, 100191, China. .,National Clinical Research Center for Mental Disorders, Key Laboratory for Mental Health, National Health Commission, Beijing, 100191, China.
| |
Collapse
|
7
|
Ohshima Y, Iwata K, Ibi M, Matsumoto M, Katsuyama M, Yabe-Nishimura C. Nicotine and methyl vinyl ketone, major components of cigarette smoke extracts, increase protective amyloid-β peptides in cells harboring amyloid-β precursor protein. J Toxicol Sci 2018; 43:257-266. [PMID: 29618714 DOI: 10.2131/jts.43.257] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
The increased ratio of longer amyloid-β (Aβ1-42)/shorter amyloid-β (Aβ1-40) peptides, generated from amyloid precursor protein (APP), is known to promote the development of Alzheimer's disease (AD). To investigate the role of smoking in Aβ production, we determined the production of Aβ species in the presence of nicotine or methyl vinyl ketone (MVK), major components of cigarette smoke extracts, in Flp-In™ T-REx™-293 (T-REx293) cells harboring a single copy of human APP. While treatment with nicotine or MVK did not affect the amount of APP, the levels of Aβ1-40 in the culture media were significantly increased. On the other hand, the levels of Aβ1-42 were unaltered by nicotine or MVK treatment. The Aβ1-42/Aβ1-40 ratio was therefore attenuated by cigarette smoke extracts. Similar results were obtained in T-REx293 cells harboring APP of Swedish- or London-type mutation linked to familial AD. T-REx293 cells expressed the nicotinic acetylcholine receptor (nAchR) and tubocurarine, an nAChR antagonist, completely blocked the effects of nicotine. Treatment with nicotine significantly elevated cellular levels of β-secretase that cleaves APP prior to Aβ generation. Taken together, a protective role of nicotine against AD pathology was suggested by enhanced extracellular Aβ1-40 production, which may suppress Aβ fibrillogenesis.
Collapse
Affiliation(s)
- Yoichi Ohshima
- Department of Pharmacology, Kyoto Prefectural University of Medicine.,Department of Neurology, Kyoto Yamashiro General Medical Center
| | - Kazumi Iwata
- Department of Pharmacology, Kyoto Prefectural University of Medicine
| | - Masakazu Ibi
- Department of Pharmacology, Kyoto Prefectural University of Medicine
| | - Misaki Matsumoto
- Department of Pharmacology, Kyoto Prefectural University of Medicine
| | | | | |
Collapse
|
8
|
Qin J, Jo DG, Cho M, Lee Y. Monitoring of early diagnosis of Alzheimer's disease using the cellular prion protein and poly(pyrrole-2-carboxylic acid) modified electrode. Biosens Bioelectron 2018; 113:82-87. [DOI: 10.1016/j.bios.2018.04.061] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2018] [Revised: 04/27/2018] [Accepted: 04/30/2018] [Indexed: 12/01/2022]
|
9
|
Ohshima Y, Taguchi K, Mizuta I, Tanaka M, Tomiyama T, Kametani F, Yabe-Nishimura C, Mizuno T, Tokuda T. Mutations in the β-amyloid precursor protein in familial Alzheimer's disease increase Aβ oligomer production in cellular models. Heliyon 2018; 4:e00511. [PMID: 29560429 PMCID: PMC5857613 DOI: 10.1016/j.heliyon.2018.e00511] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2017] [Revised: 01/05/2018] [Accepted: 01/08/2018] [Indexed: 12/29/2022] Open
Abstract
Soluble oligomers of amyloid-β (Aβ) peptides (AβOs) contribute to neurotoxicity in Alzheimer’s disease (AD). However, it currently remains unknown whether an increase in AβOs is the common phenotype in cellular and animal models. Furthermore, it has not yet been established whether experimental studies conducted using models overexpressing mutant genes of the amyloid precursor protein (APP) are suitable for investigating the underlying molecular mechanism of AD. We herein employed the Flp-In™ T-REx™-293 (T-REx 293) cellular system transfected with a single copy of wild-type, Swedish-, Dutch-, or London-type APP, and quantified the levels of Aβ monomers (Aβ1-40 and Aβ1-42) and AβOs using an enzyme-linked immunosorbent assay (ELISA). The levels of extracellular AβOs were significantly higher in Dutch- and London-type APP-transfected cells than in wild-type APP-transfected cells. Increased levels were also observed in Swedish-type APP-transfected cells. On the other hand, intracellular levels of AβOs were unaltered among wild-type and mutant APP-transfected cells. Intracellular levels of Aβ monomers were undetectable, and no common abnormality was observed in their extracellular levels or ratios (Aβ1-42/Aβ1-40) among the cells examined. We herein demonstrated that increased levels of extracellular AβOs are the common phenotype in cellular models harboring different types of APP mutations. Our results suggest that extracellular AβOs play a key role in the pathogenesis of AD.
Collapse
Affiliation(s)
- Yoichi Ohshima
- Department of Neurology, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kamikyo-ku, Kyoto 602-8566, Japan.,Department of Neurology, Kyoto Yamashiro General Medical Center, 1-27 Kizu station, Kizugawa, Kyoto, 619-0214, Japan
| | - Katsutoshi Taguchi
- Department of Anatomy and Neurobiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kamikyo-ku, Kyoto 602-8566, Japan
| | - Ikuko Mizuta
- Department of Neurology, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kamikyo-ku, Kyoto 602-8566, Japan
| | - Masaki Tanaka
- Department of Anatomy and Neurobiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kamikyo-ku, Kyoto 602-8566, Japan
| | - Takami Tomiyama
- Department of Neuroscience, Osaka City University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka, 545-8585, Japan
| | - Fuyuki Kametani
- Department of Dementia and Higher Brain Function, Tokyo Metropolitan Institute of Medical Science, 2-1-6 Kamikitazawa, Setagaya-ku, Tokyo 156-8506, Japan
| | - Chihiro Yabe-Nishimura
- Department of Pharmacology, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kamikyo-ku, Kyoto 602-8566, Japan
| | - Toshiki Mizuno
- Department of Neurology, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kamikyo-ku, Kyoto 602-8566, Japan
| | - Takahiko Tokuda
- Department of Neurology, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kamikyo-ku, Kyoto 602-8566, Japan.,Department of Molecular Pathobiology of Brain Diseases, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kamikyo-ku, Kyoto 602-8566, Japan
| |
Collapse
|
10
|
Amyloid β oligomers (AβOs) in Alzheimer's disease. J Neural Transm (Vienna) 2017; 125:177-191. [PMID: 29196815 DOI: 10.1007/s00702-017-1820-x] [Citation(s) in RCA: 91] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2017] [Accepted: 11/27/2017] [Indexed: 01/01/2023]
Abstract
The causative role of amyloid β 1-42 (Aβ42) aggregation in the pathogenesis of Alzheimer's disease (AD) has been under debate for over 25 years. Primarily, scientific efforts have focused on the dyshomeostasis between production and clearance of Aβ42. This imbalance may result from mutations either in genes for the substrate, i.e., amyloid precursor protein or in genes encoding presenilin, the enzyme of the reaction that generates Aβ42. Currently, it is supposed that soluble oligomers of amyloid beta (AβOs) and not fibrillar Aβ42 within neuritic plaques may be the toxic factors acting on a very early stage of AD, perhaps even initiating pathological cascade. For example, soluble AβOs isolated from AD patients' brains reduced number of synapses, inhibited long-term potentiation, and enhanced long-term synaptic depression in brain regions responsible for memory in animal models of AD. Concentrations of AβOs in the cerebrospinal fluid (CSF) of AD patients are often reported higher than in non-demented controls, and show a negative correlation with mini-mental state examination scores. Furthermore, increased Aβ42/oligomer ratio in the CSF of AD/MCI patients indicated that the presence of soluble AβOs in CSF may be linked to lowering of natively measured monomeric Aβ42 by epitopes masking, and hence, concentrations of AβOs in the CSF are postulated to as useful AD biomarkers.
Collapse
|
11
|
Electrochemical immunoassay for amyloid-beta 1–42 peptide in biological fluids interfacing with a gold nanoparticle modified carbon surface. Catal Today 2017. [DOI: 10.1016/j.cattod.2017.02.039] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
|
12
|
Aβ levels in the jugular vein and high molecular weight Aβ oligomer levels in CSF can be used as biomarkers to indicate the anti-amyloid effect of IVIg for Alzheimer's disease. PLoS One 2017; 12:e0174630. [PMID: 28394917 PMCID: PMC5386327 DOI: 10.1371/journal.pone.0174630] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2016] [Accepted: 03/13/2017] [Indexed: 11/19/2022] Open
Abstract
Intravenous immunoglobulin (IVIg) has been a candidate as a potential anti-amyloid immunotherapy for Alzheimer disease (AD) because it contains anti-amyloid β (Aβ) antibodies. Although several studies with IVIg in AD have been published, changing levels of Aβ efflux from the brain, or disaggregation of Aβ species induced by immunotherapy, have not been properly investigated. Here, we carried out an open label study of therapy with IVIg in five patients with AD. We collected plasma from a peripheral vein (peripheral-plasma) and from the internal jugular vein (jugular-plasma) to estimate directly the efflux of soluble Aβ from the brain. We also measured high molecular weight (HMW) Aβ oligomers in CSF as a marker to detect disaggregated Aβ. IVIg infusions were well tolerated in the majority of cases. However, one study subject had epileptic seizures after IVIg. Levels of HMW CSF Aβ oligomers in all participants were significantly increased after IVIg. Aβ40 and Aβ42 levels in jugular-plasma were continuously or temporarily elevated after treatment in three of five patients who showed preserved cognitive function, whereas levels of those in peripheral-plasma did not correlate with reactivity to the treatment. Other conventional biomarkers including 11C-Pittsburgh compound B retention were not altered after the treatment. These findings imply that HMW Aβ oligomer levels could be a better biomarker to reflect the anti-amyloid effects of IVIg than conventional Aβ species; moreover, Aβ in jugular-plasma seems to be a more direct and precise biomarker to estimate clearance of Aβ from the brain rather than Aβ in peripheral-plasma. TRIAL REGISTRATION UMIN000022319.
Collapse
|
13
|
Park MC, Kim M, Lim GT, Kang SM, An SSA, Kim TS, Kang JY. Droplet-based magnetic bead immunoassay using microchannel-connected multiwell plates (μCHAMPs) for the detection of amyloid beta oligomers. LAB ON A CHIP 2016; 16:2245-53. [PMID: 27185215 DOI: 10.1039/c6lc00013d] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
Multiwell plates are regularly used in analytical research and clinical diagnosis but often require laborious washing steps and large sample or reagent volumes (typically, 100 μL per well). To overcome such drawbacks in the conventional multiwell plate, we present a novel microchannel-connected multiwell plate (μCHAMP) that can be used for automated disease biomarker detection in a small sample volume by performing droplet-based magnetic bead immunoassay inside the plate. In this μCHAMP-based immunoassay platform, small volumes (30-50 μL) of aqueous-phase working droplets are stably confined within each well by the simple microchannel structure (200-300 μm in height and 0.5-1 mm in width), and magnetic beads are exclusively transported into an adjacent droplet through the oil-filled microchannels assisted by a magnet array aligned beneath and controlled by a XY-motorized stage. Using this μCHAMP-based platform, we were able to perform parallel detection of synthetic amyloid beta (Aβ) oligomers as a model analyte for the early diagnosis of Alzheimer's disease (AD). This platform easily simplified the laborious and consumptive immunoassay procedure by achieving automated parallel immunoassay (32 assays per operation in 3-well connected 96-well plate) within 1 hour and at low sample consumption (less than 10 μL per assay) with no cumbersome manual washing step. Moreover, it could detect synthetic Aβ oligomers even below 10 pg mL(-1) concentration with a calculated detection limit of ∼3 pg mL(-1). Therefore, the μCHAMP and droplet-based magnetic bead immunoassay, with the combination of XY-motorized magnet array, would be a useful platform in the diagnosis of human disease, including AD, which requires low consumption of the patient's body fluid sample and automation of the entire immunoassay procedure for high processing capacity.
Collapse
Affiliation(s)
- Min Cheol Park
- Center for BioMicrosystems, Brain Science Institute, Korea Institute of Science and Technology, Seoul 02792, Republic of Korea.
| | | | | | | | | | | | | |
Collapse
|
14
|
Bilousova T, Miller CA, Poon WW, Vinters HV, Corrada M, Kawas C, Hayden EY, Teplow DB, Glabe C, Albay R, Cole GM, Teng E, Gylys KH. Synaptic Amyloid-β Oligomers Precede p-Tau and Differentiate High Pathology Control Cases. THE AMERICAN JOURNAL OF PATHOLOGY 2016; 186:185-98. [PMID: 26718979 DOI: 10.1016/j.ajpath.2015.09.018] [Citation(s) in RCA: 90] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/13/2015] [Revised: 08/28/2015] [Accepted: 09/01/2015] [Indexed: 01/03/2023]
Abstract
Amyloid-β (Aβ) and hyperphosphorylated tau (p-tau) aggregates form the two discrete pathologies of Alzheimer disease (AD), and oligomeric assemblies of each protein are localized to synapses. To determine the sequence by which pathology appears in synapses, Aβ and p-tau were quantified across AD disease stages in parietal cortex. Nondemented cases with high levels of AD-related pathology were included to determine factors that confer protection from clinical symptoms. Flow cytometric analysis of synaptosome preparations was used to quantify Aβ and p-tau in large populations of individual synaptic terminals. Soluble Aβ oligomers were assayed by a single antibody sandwich enzyme-linked immunosorbent assay. Total in situ Aβ was elevated in patients with early- and late-stage AD dementia, but not in high pathology nondemented controls compared with age-matched normal controls. However, soluble Aβ oligomers were highest in early AD synapses, and this assay distinguished early AD cases from high pathology controls. Overall, synapse-associated p-tau did not increase until late-stage disease in human and transgenic rat cortex, and p-tau was elevated in individual Aβ-positive synaptosomes in early AD. These results suggest that soluble oligomers in surviving neocortical synaptic terminals are associated with dementia onset and suggest an amyloid cascade hypothesis in which oligomeric Aβ drives phosphorylated tau accumulation and synaptic spread. These results indicate that antiamyloid therapies will be less effective once p-tau pathology is developed.
Collapse
Affiliation(s)
- Tina Bilousova
- University of California Los Angeles School of Nursing, Los Angeles, California; Mary S. Easton Center for Alzheimer's Research at the University of California Los Angeles, Los Angeles, California
| | - Carol A Miller
- Departments of Pathology, Neurology, and the Program in Neuroscience, University of Southern California Keck School of Medicine, Los Angeles, California
| | - Wayne W Poon
- Institute for Memory Impairments and Neurological Disorders, University of California Irvine, Irvine, California
| | - Harry V Vinters
- Department of Neurology, University of California Los Angeles School of Medicine, Los Angeles, California; Department of Pathology and Laboratory Medicine, University of California Los Angeles School of Medicine, Los Angeles, California
| | - Maria Corrada
- Institute for Memory Impairments and Neurological Disorders, University of California Irvine, Irvine, California; Department of Neurology, University of California Irvine, Irvine, California
| | - Claudia Kawas
- Institute for Memory Impairments and Neurological Disorders, University of California Irvine, Irvine, California; Department of Neurology, University of California Irvine, Irvine, California; Department of Neurobiology & Behavior, University of California Irvine, Irvine, California
| | - Eric Y Hayden
- Mary S. Easton Center for Alzheimer's Research at the University of California Los Angeles, Los Angeles, California; Department of Neurology, University of California Los Angeles School of Medicine, Los Angeles, California
| | - David B Teplow
- Mary S. Easton Center for Alzheimer's Research at the University of California Los Angeles, Los Angeles, California; Department of Neurology, University of California Los Angeles School of Medicine, Los Angeles, California
| | - Charles Glabe
- Department of Molecular Biology and Biochemistry, University of California Irvine, Irvine, California
| | - Ricardo Albay
- Department of Molecular Biology and Biochemistry, University of California Irvine, Irvine, California
| | - Gregory M Cole
- Mary S. Easton Center for Alzheimer's Research at the University of California Los Angeles, Los Angeles, California; Department of Neurology, University of California Los Angeles School of Medicine, Los Angeles, California; Department of Medicine, University of California Los Angeles School of Medicine, Los Angeles, California; Geriatric Research, Education and Clinical Center, VA Greater Los Angeles Healthcare System, Los Angeles, California
| | - Edmond Teng
- Mary S. Easton Center for Alzheimer's Research at the University of California Los Angeles, Los Angeles, California; Department of Neurology, University of California Los Angeles School of Medicine, Los Angeles, California; Geriatric Research, Education and Clinical Center, VA Greater Los Angeles Healthcare System, Los Angeles, California
| | - Karen H Gylys
- University of California Los Angeles School of Nursing, Los Angeles, California; Mary S. Easton Center for Alzheimer's Research at the University of California Los Angeles, Los Angeles, California.
| |
Collapse
|
15
|
Electrochemical detection of amyloid-β oligomer with the signal amplification of alkaline phosphatase plus electrochemical–chemical–chemical redox cycling. J Electroanal Chem (Lausanne) 2015. [DOI: 10.1016/j.jelechem.2015.06.017] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
|
16
|
Shi C, Zhu X, Wang J, Long D. Estrogen receptor α promotes non-amyloidogenic processing of platelet amyloid precursor protein via the MAPK/ERK pathway. J Steroid Biochem Mol Biol 2014; 144 Pt B:280-5. [PMID: 25017047 DOI: 10.1016/j.jsbmb.2014.06.010] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/12/2014] [Revised: 06/14/2014] [Accepted: 06/21/2014] [Indexed: 02/03/2023]
Abstract
Deposition of amyloid β peptide (Aβ), a proteolytic product of amyloid precursor protein (APP), in senile plaques and in the walls of cerebral blood vessels is a hallmark of Alzheimer's disease (AD). Platelets contain high levels of APP and Aβ and may contribute to amyloid deposits seen in AD. However, the biochemical mechanism(s) involved in the regulation of platelet APP metabolism are largely unknown. The estrogen receptor α (ERα) is found to be expressed in platelets. It has not been elucidated whether ERα-mediated non-genomic signaling intervenes with platelet APP processing. Using ERα knock-out (α-ERKO) mice and wild type (WT) littermates, the present study demonstrated that ERα-specific agonist propylpyrazole triol (PPT) promoted non-amyloidogenic processing of platelet APP via the mitogen-activated protein kinase (MAPK)/extracellular-signal-regulated kinase (ERK) pathway. The underlying basis involves direct association of activated ERK with a disintegrin and metalloprotease domain 17 (ADAM17, an α-secretase candidate) and ERK-dependent threonine phosphorylation of ADAM17. These results suggest that selective modulation of ERα in peripheral target tissues may serve as an anti-amyloidogenic strategy for AD and other amyloidogenic diseases.
Collapse
Affiliation(s)
- Chun Shi
- Department of Anatomy, Guangzhou Medical University, Guangzhou, Guangdong 510182, China.
| | - XiaoMing Zhu
- Faculty of Chinese Medicine, Macau University of Science and Technology, Macau, China
| | - Jisheng Wang
- Department of Anatomy, Guangzhou Medical University, Guangzhou, Guangdong 510182, China
| | - Dahong Long
- Department of Anatomy, Guangzhou Medical University, Guangzhou, Guangdong 510182, China
| |
Collapse
|
17
|
Williams S, Schulz P, Sierks MR. A sensitive phage-based capture ELISA for sub-femtomolar detection of protein variants directly from biological samples. Biotechnol Prog 2014; 31:289-98. [PMID: 25203940 DOI: 10.1002/btpr.1987] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2014] [Revised: 08/25/2014] [Indexed: 12/16/2022]
Abstract
To determine the role of proteins, and in particular protein variants, in human health, it may often be necessary to quantitatively determine the concentration of a specific protein variant present in complex biological samples such as blood, cerebral spinal fluid (CSF), or tissue. Many protein variants are present only at trace levels and therefore a simple assay with very high sensitivity and reliability would greatly facilitate correlation of the presence of particular protein variants with the progression of specific diseases. We have developed a simple phage based capture ELISA system that enables femtomolar or better detection of individual protein variants directly from complex biological samples. The protocol utilizes a capture reagent that selectively recognizes a unique epitope of the protein variant and a phage based detection reagent that binds to a second epitope present in all forms of the target protein. The phage based detection reagent is essentially a self-assembling nanoparticle consisting of several thousand coat proteins that can each be labeled to amplify the detection signal by several orders of magnitude. Here we demonstrate that we can achieve subfemtomolar detection of individual protein variants that have been implicated in neurodegenerative disease directly from complex tissue homogenates and sera. The ELISA system should facilitate identification of disease specific protein variants or other compounds even when present at trace amounts in samples including blood, CSF, saliva and urine.
Collapse
Affiliation(s)
- Stephanie Williams
- Chemical Engineering, The School for Engineering of Matter, Transport and Energy, Arizona State University, Tempe, AZ 85287-6106
| | | | | |
Collapse
|